First Responder page header.jpg
First responder thumbnail.jpg

First Responder

First Responder Antibodies from BBI Solutions

At BBI Solutions, we offer an exclusive range of monoclonal antibodies to a diverse set of biothreat targets to ensure the reliability and performance of your critical diagnostic assays. Our range is recommended for use in ELISA and lateral flow.  

BBI Solutions’ monoclonal antibodies for both biothreat infectious agents and explosives are exclusive and cost-efficient products for assay developers, manufacturers and researchers worldwide. All are manufactured in-house at BBI under ISO13485:2016. 

Biothreat infectious targets include Burkholderia, Brucella, Coxiella, Ebola and the causative agents of Anthrax and Plague (Bacillus anthracis and Y.pestis). Explosive targets include TNT, PETN and RDX. 

Please contact our Customer Services Team directly to discuss your requirements on tel:+44 (0) 1495 363000 or alternatively you can submit an enquiry here.

Applications for First Responder Antibodies

At BBI Solutions, we offer an exclusive range of monoclonal antibodies to a diverse set of biothreat targets to ensure the reliability and performance of your critical diagnostic assays.  Our range is recommended for use in ELISA and lateral flow. 

BBI Solutions’ monoclonal antibodies for both biothreat infectious agents and explosives are exclusive and cost-efficient products for assay developers, manufacturers and researchers worldwide. All are manufactured in-house at BBI under ISO13485:2016.

Biothreat infectious targets include Burkholderia, Brucella, Coxiella, Ebola and the causative agents of Anthrax and Plague (Bacillus anthracis and Y.pestis).   Explosive targets include TNT, PETN and RDX. 

Technical Documents

If you require any further product specific technical information or datasheets please submit your request to our technical team here 

There are currently no documents in this category.
There are currently no documents in this category.
There are currently no documents in this category.
There are currently no documents in this category.
There are currently no documents in this category.
There are currently no documents in this category.
There are currently no documents in this category.
There are currently no documents in this category.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox